非霍奇金淋巴瘤（NHL）总体治疗效果欠佳，有必要寻找新的治疗靶点。神经元特异性烯醇化酶(NSE)是一种关键的糖酵解酶，与恶性肿瘤关系密切。我们前期临床研究表明，它在NHL各病理亚型中高表达,且血清NSE水平与治疗反应性相关，治疗前血清NSE水平是NHL患者独立的预后因子。此外，在体外实验中，我们应用RNA干扰技术初步发现沉默NSE基因能抑制NHL细胞的增殖，但是，具体机制尚不清楚。为此，本项目拟在细胞及动物水平，采用不同的表达质粒改变NSE酶活性，借助激光共聚焦、PCR、western-blot等分子生物学技术，探索酶活性改变对细胞、移植瘤生长和糖酵解途径等的影响，以及与细胞周期、凋亡、生长通路改变的关系，从而阐明以NSE为靶点抗淋巴瘤的作用及确切机制，为开辟淋巴瘤治疗的新方向提供理论依据。

The overall management effect for non-Hodgkin's lymphoma is still poor, so it is necessary to explore new targets on treatment. Neuron-specific enolase (NSE) is a key glycolytic enzyme, closely associated with malignant tumors.Our previous studies showed that it was expressed in any histological subtype of NHL, and the outcome was significantly worst in the NSE increased group than in the NSE normal group.And pretreatment serum NSE level was taken as an independent prognostic factor for NHL. Furthermore, we found that RNA interference which is used to silence NSE gene can inhibit NHL cell proliferation, but the mechanisms are unclear. To solve the scientific problem,this project is to take the DoHH2 human B lymphoma as targeted cells and establish the subcutaneous transplanted tumor model in the CB-17SCID mice, then explore the change of glycolytic levels,key enzymes and mitochondrial membrane potentials as well as cell cycle, apoptosis and growth pathway through various molecular biological techniques when NSE activity is modified by different expressing plasmid , which subsequently will clarify the exact mechanism of inhibiting proliferation of lymphoma cells and develop a valuable strategy for seeking new management targets on the lymphoma.